New drug trial aims to help teens with painful skin condition
NCT ID NCT06768671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers will also check if it helps reduce symptoms over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sonelokimab (a drug given as an injection under the skin)
What this could lead to
If it works, this could provide a new treatment option for teenagers with moderate to severe hidradenitis suppurativa.
What could go wrong
This is a small, early-stage study in 35 teens, so results may not apply to everyone. The drug may cause side effects or not work as well as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
North Little Rock, Arkansas, 72117, United States
-
Clinical Site
Stanford, California, 94304, United States
-
Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Clinical Site
Hollywood, Florida, 33201, United States
-
Clinical Site
Miami, Florida, 33136, United States
-
Clinical Site
Macon, Georgia, 31217, United States
-
Clinical Site
Sandy Springs, Georgia, 30328, United States
-
Clinical Site
Chicago, Illinois, 60611, United States
-
Clinical Site
Columbus, Indiana, 47201, United States
-
Clinical Site
Murray, Kentucky, 42071, United States
-
Clinical Site
Waterford, Michigan, 48328, United States
-
Clinical Site
Fargo, North Dakota, 58103, United States
-
Clinical Site
Charleston, South Carolina, 29425, United States
-
Clinical Site
Dallas, Texas, 75246, United States
-
Clinical Site
Dallas, Texas, 75390-8575, United States
-
Clinical Site
San Antonio, Texas, 78218, United States
-
Clinical Site
Norfolk, Virginia, 23502, United States
-
Clinical Site
Seattle, Washington, 98105, United States